Trial Profile
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF TAS-116 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Pimitespib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms CHAPTER-GIST-301
- Sponsors Taiho Pharmaceutical
- 20 Jun 2022 According to a Taiho Pharmaceutical media release, based on the data from this study, company has obtained manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for the oral heat shock protein (HSP) 90 inhibitor Jeselhy Tablets 40 mg for the indication of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.
- 07 Jun 2022 Status changed from not yet recruiting to completed, according to Results published in the Annals of Oncology.
- 07 Jun 2022 Results assessing efficacy and safety of pimitespib in advanced GIST were published in the Annals of Oncology.